Kronos Bio Stock Analysis

Kronos Stock Analysis Notes

About 27.0% of the company outstanding shares are owned by corporate insiders. The company has price-to-book ratio of 0.52. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Kronos Bio recorded a loss per share of 1.43. The entity had not issued any dividends in recent years. The firm had 3:2 split on the 3rd of November 2003. Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company was incorporated in 2017 and is headquartered in San Mateo, California. Kronos Bio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 101 people. To find out more about Kronos Bio contact Norbert Bischofberger at (650) 781-5200 or learn more at https://www.kronosbio.com.

Kronos Bio Investment Alerts

Kronos Bio Upcoming and Recent Events

Kronos Largest EPS Surprises

View All Earnings Estimates

Kronos Stock Institutional Investors

Note, although Kronos Bio's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Kronos Market Capitalization

The company currently falls under 'Micro-Cap' category with a current market capitalization of 57.93 M.

Kronos Profitablity

Management Efficiency

Kronos Bio has return on total asset (ROA) of (0.2828) % which means that it has lost $0.2828 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.63) %, meaning that it created substantial loss on money invested by shareholders. Kronos Bio's management efficiency ratios could be used to measure how well Kronos Bio manages its routine affairs as well as how well it operates its assets and liabilities. As of the 29th of November 2024, Return On Tangible Assets is likely to drop to -0.55. In addition to that, Return On Capital Employed is likely to drop to -0.68. At this time, Kronos Bio's Total Assets are very stable compared to the past year. As of the 29th of November 2024, Non Current Assets Total is likely to grow to about 42.7 M, while Net Tangible Assets are likely to drop about 225.4 M.

Technical Drivers

As of the 29th of November, Kronos Bio secures the Mean Deviation of 2.63, downside deviation of 4.12, and Risk Adjusted Performance of 0.008. Kronos Bio technical analysis lets you operate historical price patterns with an objective to determine a pattern that forecasts the direction of the firm's future prices.

Kronos Bio Price Movement Analysis

Kronos Bio Insider Trading Activities

Kronos Bio Outstanding Bonds

Kronos Bio Predictive Daily Indicators

Kronos Bio Forecast Models

Kronos Bio's time-series forecasting models are one of many Kronos Bio's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Kronos Bio's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how Kronos Bio prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Kronos shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Kronos Bio. By using and applying Kronos Stock analysis, traders can create a robust methodology for identifying Kronos entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Kronos analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Kronos analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Kronos Bio stock analysis indicators help investors evaluate how Kronos Bio stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Kronos Bio shares will generate the highest return on investment. By understating and applying Kronos Bio stock analysis, traders can identify Kronos Bio position entry and exit signals to maximize returns.

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kronos Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. To learn how to invest in Kronos Stock, please use our How to Invest in Kronos Bio guide.You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kronos Bio. If investors know Kronos will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Kronos Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

The market value of Kronos Bio is measured differently than its book value, which is the value of Kronos that is recorded on the company's balance sheet. Investors also form their own opinion of Kronos Bio's value that differs from its market value or its book value, called intrinsic value, which is Kronos Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kronos Bio's market value can be influenced by many factors that don't directly affect Kronos Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Kronos Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Kronos Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kronos Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.